These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38283962)

  • 21. Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England.
    Abner S; Gillies CL; Shabnam S; Zaccardi F; Seidu S; Davies MJ; Adeyemi T; Khunti K; Webb DR
    Cardiovasc Diabetol; 2022 Jan; 21(1):8. PubMed ID: 35012531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes with poor-control HbA1c is cardiovascular disease 'risk equivalent' for mortality: UK Biobank and Hong Kong population-based cohort study.
    Wan EYF; Yu EYT; Mak IL; Youn HM; Chan KS; Chan EWY; Wong ICK; Lam CLK
    BMJ Open Diabetes Res Care; 2023 Jan; 11(1):. PubMed ID: 36634978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ProtecT-2-D trial protocol: cardiovascular protection in patients with type 2 diabetes and established heart and/or vascular disease at a cardio-metabolic clinic-a randomized controlled trial.
    Overgaard KS; Mohamed RA; Andersen TR; Lambrechtsen J; Egstrup K; Auscher S
    Cardiovasc Diabetol; 2024 Jul; 23(1):241. PubMed ID: 38978117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness.
    Smith R; Han L; Ali S; Prady SL; Taylor J; Hughes T; Ajjan RA; Siddiqi N; Doran T
    J Psychiatr Ment Health Nurs; 2019 Nov; 26(9-10):347-357. PubMed ID: 31287193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
    Deerochanawong C; Chan SP; Matawaran BJ; Sheu WH; Chan J; Man NH; Suastika K; Khoo CM; Yoon KH; Luk A; Mithal A; Linong J
    Diabetes Obes Metab; 2019 Nov; 21(11):2354-2367. PubMed ID: 31264765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
    Scheen AJ
    Expert Rev Clin Pharmacol; 2023; 16(11):1053-1062. PubMed ID: 37919944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings.
    Wright AK; Suarez-Ortegon MF; Read SH; Kontopantelis E; Buchan I; Emsley R; Sattar N; Ashcroft DM; Wild SH; Rutter MK
    Circulation; 2020 Nov; 142(20):1925-1936. PubMed ID: 33196309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. All-cause mortality and cardiovascular events in a Spanish nonagenarian cohort according to type 2 diabetes mellitus status and established cardiovascular disease.
    Salinero-Fort MA; Mostaza J; Lahoz C; Cárdenas-Valladolid J; Vicente-Díez JI; Gómez-Campelo P; de Miguel-Yanes JM
    BMC Geriatr; 2022 Mar; 22(1):224. PubMed ID: 35303825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Community-based care for the management of type 2 diabetes: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(23):1-40. PubMed ID: 23074528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial.
    Munch L; Bennich BB; Overgaard D; Konradsen H; Middelfart H; Kaarsberg N; Knop FK; Vilsbøll T; Røder ME
    Diabet Med; 2019 Jul; 36(7):854-861. PubMed ID: 30614066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes.
    Boersma HE; van Waateringe RP; van der Klauw MM; Graaff R; Paterson AD; Smit AJ; Wolffenbuttel BHR
    BMC Endocr Disord; 2021 Jan; 21(1):14. PubMed ID: 33435948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus.
    Moon MK; Noh J; Rhee EJ; Park SH; Kim HC; Kim BJ; Kim HJ; Choi S; Na JO; Hyun YY; Kim BJ; Han KD; Jeong IK
    Diabetes Metab J; 2023 Jan; 47(1):45-58. PubMed ID: 36727163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.